Skip to content

ALLERGOS

Active Private limited companyfounded 2008active for 18 yearsChaussée d'Audenarde 133a, 7742 PecqKBO/BCE: BE 0806.486.605

Lifetime

17 annual accounts with figures on one time axis
peak €146,835 (2018)
€109,163▼ 5.1%
lowest -€109,350 (2016)
€29,652▼ 10.8%
peak €111,192 (2025)
€111,192▲ 36.4%
€659,443▼ 5.8%
Board2 names since 2008
1 director
Documentsfilings and deeds
04-09-202635 days late
2025micro format
Equity from €81,540 to €111,192Cash from €49,407 to €71,064

Key points

from the 2025 annual accounts

Equity

€111,192 ▲ 36.4%

ALLERGOS has made a profit without a break since 2017.

Debts

€659,443 86% of the balance sheet
Financial debts 88%Suppliers 0%Taxes and wages 2%Other 10%

Of this, €79,271 falls due within a year.

Filings

17 annual accounts since 2009
AprilJune31 JulyOctober2010201520202025

Six of the last ten came late. The 2025 accounts came latest: 35 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 4,107 companies had the same profile as ALLERGOS has now. Each dot stands for 11 companies, two years later.

97.9%
were still trading
0.9%
stopped another way
1.0%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 10 to 30%
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 4,107 companies, not a prediction for ALLERGOS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 18-09-2008
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0806486605
Reappointment: (director) “L'exercice de la médecine et plus particulièrement de la pneumologie ainsi que toutes activités d'études et de…” (deed in French) · Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 03-05-2023 · Gazette deed
Registered office moved from Bailleul to Hérinnes New registered office: Chaussée d'Audenarde, 133A à 7742 Hérinnes · Previous registered office: Rue Marcel Nottebaert, 1C à 7730 Bailleul · General meeting of 30-01-2016 · Gazette deed
Incorporation published on 30-09-2008 · Gazette deed
All 28 events

Comparable companies

same main activity, similar in size and age
Company
ALLERGOS Pecq €770,635 €109,163 14.4% -
LG Xpert Esneux €728,630 €109,057 29.1% -
Dokter Joost De Ganck - Urologie Lochristi €799,535 €112,810 68.2% -
Van Daele - Devroey Aalst €800,361 €115,261 98.8% -
Société de radiologie du Dr TSHIBANDA Chaudfontaine €718,805 €112,365 86.0% -
Dr. Anne D'Hooghe Bruges €721,021 €112,298 77.4% -
DR. VAN DE WALLE - DR. VAN DAMME Schoten €783,456 €119,125 91.2% -

These companies have the same main activity as ALLERGOS: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €719,000 and €800,000, founded between 2007 and 2009.

Official details

Source: KBO
Status
Active since 18-09-2008Normal situation
Activity
Specialist medical practiceNACE 86220and 2 others
Financial year end
31 December
Peppol
Reachable since 12-12-2025
Company details

Annual accounts 2025

≈ €200,000estimated
€770,635▼ 1.4%
Filing
Filed on 04-09-2026
Financials

Insights on ALLERGOS

ALLERGOS files the micro format. That format states no turnover. The gross margin rose from €34,736 in 2009 to €109,163 in 2025.

The balance sheet grew most in 2016 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about ALLERGOS

What is the company number of ALLERGOS?
The company number of ALLERGOS is 0806.486.605. The VAT number is the same number with BE in front: BE 0806.486.605.
Where is ALLERGOS based?
The registered office is at Chaussée d'Audenarde 133a, 7742 Pecq.Company details
What does ALLERGOS do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of ALLERGOS?
ALLERGOS is a private limited company (BV).
When was ALLERGOS founded?
ALLERGOS was founded on 18-09-2008.
Is ALLERGOS still active?
Yes, ALLERGOS is an active enterprise in the KBO register.
What is the turnover of ALLERGOS?
The turnover in financial year 2025 is ≈ €200,000. This figure is estimated from the gross margin of €109,163 and 40 comparable companies (NACE 86220). It probably lies between €170,000 and €270,000. In financial year 2018 turnover was €260,157.Financials
Is ALLERGOS profitable?
In financial year 2025, ALLERGOS made a profit of €29,652.
Where can I find the annual accounts of ALLERGOS?
ALLERGOS filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of ALLERGOS due?
ALLERGOS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.